Showing 12 posts of 12 posts found.

AI accurately detects subtle signs of atrial fibrillation even in normal tests

August 2, 2019
Medical Communications AF, AI, ECG, atrial fibrillation, electrcardiogram, pharma

A new study from the Mayo Clinic shows that artificial intelligence (AI) can detect signs of atrial fibrillation (AF) in …

Gamification: what’s in it for the pharma industry?

October 6, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AF, Boehringer, COPD, CRUK, Gamification, ROI, Syrum, digital

Gamification is the new buzzword in digital marketing and has the potential to engage consumers more than traditional strategies. This …


Pradaxa ‘safe’ says Australian regulator

August 6, 2014
Research and Development, Sales and Marketing AF, Australia, BMJ, Pradaxa, stroke

Australia’s drug regulator says it will not be updating its safety advice for Boehringer’s Pradaxa despite mounting safety issues around …

Boehringer’s online PMCPA breach

April 25, 2013
Medical Communications, Research and Development, Sales and Marketing ABPI, AF, Boehringer, PMCPA

Boehringer Ingelheim has failed to uphold high standards, according to the PMCPA, which enforces the ABPI Code of Practice, over …

Eliquis image

Eliquis in UK for AF

December 13, 2012
Sales and Marketing AF, BMS, Eliquis, NVAF, Pfizer

Eliquis has been made available in the UK today to prevent stroke and systemic embolism in patients with nonvalvular atrial …

Xarelto image

Xarelto gets new EU approval

November 21, 2012
Sales and Marketing AF, Bayer, DVT, Xarelto

Bayer’s oral anticoagulant Xarelto has extended its licence in Europe to treat pulmonary embolism (PE) and prevent recurrent deep vein …

Merck image

Merck gives back vernakalant rights

September 28, 2012
Sales and Marketing AF, Cardiome, Merck, vernakalant

Merck has dealt a further blow to Cardiome Pharma Corp by handing back all marketing and development rights for the …

Petition launched to raise AF and stroke awareness

April 20, 2012
Business Services, Medical Communications, Sales and Marketing AF, Boehringer Ingelheim, Pradaxa, Xarelto, stroke

Various health organisations have called on more people involved in the management of atrial fibrillation (AF) to help raise awareness …

NICE set to reject Xarelto in AF

January 10, 2012
Sales and Marketing AF, NICE, Pradaxa, Xarelto, atrial fibrillation

NICE says it needs more data on Bayer’s Xarelto in order to recommend it for people with atrial fibrillation. The …

Multaq raises risk of death in permanent AF patients

November 16, 2011
Sales and Marketing AF, Multaq, Sanofi

More bad news for Sanofi’s Multaq as new data shows the drug doubles the risk of death in people with …

Boehringer agrees Pradaxa kidney function warning

October 30, 2011
Sales and Marketing AF, EMA, Pradaxa, renal function

Boehringer Ingelheim is to alert doctors in Europe of the need to check patients’ kidney function before prescribing anticoagulant Pradaxa. …

Companies join forces to promote AF awareness

February 16, 2011
Medical Communications, Sales and Marketing AF, Multaq, Pradaxa, apixaban, atrial fibrillation

Boehringer Ingelheim and Sanofi-Aventis are to co-sponsor the World Heart Federation’s global atrial fibrillation (AF) education campaign. AF AWARE was …

Latest content